MRNA Stock Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$108.85 |
| 52 Week High | US$142.79 |
| 52 Week Low | US$62.55 |
| Beta | 1.59 |
| 1 Month Change | -1.39% |
| 3 Month Change | 5.87% |
| 1 Year Change | -16.73% |
| 3 Year Change | -39.08% |
| 5 Year Change | 312.31% |
| Change since IPO | 485.22% |
Recent News & Updates
Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares
Apr 22
Moderna: Considering The Cancer Vaccine Angle
Apr 11Moderna Continues To Build A Pipeline
Apr 03Recent updates
Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares
Apr 22Moderna: Considering The Cancer Vaccine Angle
Apr 11Moderna Continues To Build A Pipeline
Apr 03Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play
Mar 27Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 27Moderna: Counting On Pipeline Too Much
Feb 23Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World
Feb 16Moderna: Fade 2025 Outlook
Jan 15Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 29Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024
Nov 03Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate
Oct 18Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 47% Discount?
May 23Shareholder Returns
| MRNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.2% | 1.0% | 1.2% |
| 1Y | -16.7% | 0.7% | 24.9% |
Price Volatility
| MRNA volatility | |
|---|---|
| MRNA Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRNA has not had significant price volatility in the past 3 months.
Volatility Over Time: MRNA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
| MRNA fundamental statistics | |
|---|---|
| Market cap | US$41.31b |
| Earnings (TTM) | -US$4.71b |
| Revenue (TTM) | US$6.85b |
6.1x
P/S Ratio-8.8x
P/E RatioIs MRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRNA income statement (TTM) | |
|---|---|
| Revenue | US$6.85b |
| Cost of Revenue | US$9.54b |
| Gross Profit | -US$2.69b |
| Other Expenses | US$2.02b |
| Earnings | -US$4.71b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -12.31 |
| Gross Margin | -39.28% |
| Net Profit Margin | -68.84% |
| Debt/Equity Ratio | 0% |
How did MRNA perform over the long term?
See historical performance and comparison